This market research report presents a detailed analysis of the key drivers and trends that influence market growth. It also segments the global heparin market by product type (LMWH and others), by route of administration (IV injection/infusion and SC injection), and by geography (the Americas, APAC, and EMEA). The key leading vendors analyzed in this market study are GlaxoSmithKline (GSK), Leo Pharma, Pfizer, and Sanofi.
Technavio’s market research analysts estimate the global heparin market, to surpass $5 billion by 2020. Heparin is a disaccharide anticoagulant or blood thinner that prevents the formation of blood clots and is produced in the body by basophils and mast cells. Heparin is available in injectable form and is used as a blood thinner to treat thrombosis or blood clot formation in the veins, arteries, or lungs. EMEA dominates the global heparin market, owing to the growing adoption of new oral anticoagulants with better safety and efficacy profiles. The side effects associated with the use of heparin products, such as heparin-induced thrombocytopenia and the complications of bleeding, play a critical role in bolstering the adoption of oral anticoagulants like dabigatran, apixaban, and rivaroxaban.
The new market research report from Technavio provides a breakdown and analysis of the heparin segments by technology.
“The extensive use of heparin as an anti-inflammatory and antitumor agent has propelled the growth of this market. The anti-inflammatory activity of heparin that prevents the metastatic spread of tumor cells is a new finding. Heparin exhibits this activity by neutralizing cationic mediators, inhibiting adhesion molecules, and inhibiting heparanase. Similarly, it has also been discovered that heparin can target P- and L-selectin and integrin activity, and prevent cancer progression. The extensive exploitation of heparin’s new therapeutic uses will result in market growth during the forecast period,” says Barath Palada, Lead Analyst, Pharma, Technavio Research
Most low molecular weight heparins (LMWH) are administered using an SC injection. The choice of SC or IV routes depends on the prescriber and medical need. SC injections are easy to administer, and hospitalization is not necessary. Consequently, they can be administered once or twice daily. The dosage is determined based on the time it takes for the blood to clot.
The leading vendors in the global heparin market are GlaxoSmithKline (GSK), Leo Pharma, Pfizer, and Sanofi. This market is highly competitive because of the presence of numerous small and large vendors. To gain market shares, the vendors are developing generic formulations for blood coagulation and other novel therapeutic areas. Companies that have the capability to manufacture drugs that can effectively treat and cure coagulation disorders and exhibit a high safety and efficacy profile are anticipated to gain maximum market traction.
A more detailed analysis is available in the Technavio report, Global Heparin Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
